Ixempra
(Ixabepilone)ApprovedSmall molecule
Ixabepilone is used to treat advanced breast cancer, either alone or in combination with other chemotherapy drugs. It works by stopping cancer cells from dividing and growing.[2] Ixempra is currently approved and in use across 43 indications[4].[1]
Ixempra is one of 818 small molecule programs targeting Glioma. It is currently in Approved.
43
Indications
99
Total Trials
3
Active Trials
817
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 43 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Ixempra
RR-Pharm
Approved
Adriamycin
GGynecologic Oncology Group
Preclinical
Gemzar
GGynecologic Oncology Group
Preclinical
MS Contin
Merck & Co.Preclinical
Zinecard
CChildren's Oncology Group
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Paracetamol
GSKPreclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer35 trials
Show 32 more trials
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer
Completed·—·Phase 1·NCT01084057·56 enrolled
Prostate Cancer5 trials
Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
Completed·—·Phase 2·NCT00828308·16 enrolled
Show 2 more trials
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
Terminated·—·Phase 2·NCT00672009·11 enrolled
Patients With Advanced Solid Tumors4 trials
Patients With Solid Tumors3 trials
Metastatic Prostate Cancer3 trials
41 more indications
Endometrial Cancer2 trials
Stomach Cancer2 trials
Solid Tumors2 trials
Primary Peritoneal Cancer2 trials
Advanced Cancers2 trials
Non-Small Cell Lung Cancer2 trials
Kidney Cancer2 trials
Pancreatic Cancer2 trials
Biomarkers1 trial
Neoadjuvant Chemotherapy1 trial
Germ Cell Tumor1 trial
Advanced Cancer1 trial
Solid Malignancies1 trial
Advanced Malignancies1 trial
Lymphoma1 trial
Recurrent Head and Neck Cancer1 trial
Advanced Solid Tumors1 trial
Leukemia1 trial
Peripheral Neuropathy1 trial
Gastric Cancer1 trial
Recurrent or Refractory Solid Tumors1 trial
Lymphoproliferative Disorders1 trial
Glioma1 trial
Leiomyosarcoma1 trial
Metastatic Colorectal Cancer1 trial
Lung Cancer1 trial
Squamous Cell Cancer of the Head and Neck1 trial
Endometrial Adenocarcinoma1 trial
Estrogen Receptor Negative1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Oct 16, 2007
IXEMPRA KIT
NDA NDA022065
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Ixempra drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Ixabepilone. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]